首页> 美国卫生研究院文献>Applied and Environmental Microbiology >Prothioconazole and Prothioconazole-Desthio Activities against Candida albicans Sterol 14-α-Demethylase
【2h】

Prothioconazole and Prothioconazole-Desthio Activities against Candida albicans Sterol 14-α-Demethylase

机译:Prothioconazole和Prothioconazole-Desthio对白色念珠菌甾醇14-α-脱甲基酶的活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prothioconazole is a new triazolinthione fungicide used in agriculture. We have used Candida albicans CYP51 (CaCYP51) to investigate the in vitro activity of prothioconazole and to consider the use of such compounds in the medical arena. Treatment of C. albicans cells with prothioconazole, prothioconazole-desthio, and voriconazole resulted in CYP51 inhibition, as evidenced by the accumulation of 14α-methylated sterol substrates (lanosterol and eburicol) and the depletion of ergosterol. We then compared the inhibitor binding properties of prothioconazole, prothioconazole-desthio, and voriconazole with CaCYP51. We observed that prothioconazole-desthio and voriconazole bind noncompetitively to CaCYP51 in the expected manner of azole antifungals (with type II inhibitors binding to heme as the sixth ligand), while prothioconazole binds competitively and does not exhibit classic inhibitor binding spectra. Inhibition of CaCYP51 activity in a cell-free assay demonstrated that prothioconazole-desthio is active, whereas prothioconazole does not inhibit CYP51 activity. Extracts from C. albicans grown in the presence of prothioconazole were found to contain prothioconazole-desthio. We conclude that the antifungal action of prothioconazole can be attributed to prothioconazole-desthio.
机译:保硫康唑是一种用于农业的新型三唑硫酮杀菌剂。我们已经使用白色念珠菌CYP51(CaCYP51)来研究丙硫康唑的体外活性,并考虑在医学领域使用此类化合物。用14mg甲基化的甾醇底物(羊毛甾醇和eburicol)的积累和麦角甾醇的消耗可以证明,用原硫代康唑,原硫代康唑-去硫基和伏立康唑处理白色念珠菌细胞会导致CYP51抑制。然后,我们比较了Prothioconazole,Prothioconazole-desthio和voriconazole与CaCYP51的抑制剂结合特性。我们观察到,按预期方式的吡咯抗真菌剂(其中II型抑制剂与血红素结合作为第六个配体),丙硫康唑-去硫基和伏立康唑与CaCYP51非竞争性结合,而丙硫康唑竞争性地结合并且没有表现出经典的抑制剂结合谱。在无细胞试验中抑制CaCYP51活性表明,丙硫康唑-去硫基具有活性,而丙硫康唑不抑制CYP51活性。发现在原硫康康唑存在下生长的白色念珠菌提取物含有原硫康康唑-去硫基。我们得出的结论是,Prothioconazole的抗真菌作用可归因于Prothioconazole-desthio。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号